參考文獻(xiàn)/References:
[1] 胡銘洋，吳綺楠，吳永忠.肝癌的靶向和免疫治療[J]. 重慶醫(yī)科大學(xué)學(xué)報(bào),2019,44(12):1547-1552.
[2] 馬婧,王霄,宋爭(zhēng)放,等.肝癌AASLD、EASL、JSH 指南及中國診療規(guī)范的比較[J]. 腫瘤的預(yù)防與治療,2019,32(11):1031-1038.
[3] Gory I，F(xiàn)ink M，Bell S，et al. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study[J]. Scand J Gastroenterol，2015，50(5): 567-576.
[4] Maucort-Boulch D,de MC C，F(xiàn)ranceschi S，et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide[J]. Int J Cancer，2018，142(12)：2471-2477.
[5] Hua C，Bei S，Wang S，et al. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB[J]. Journal of Cancer Research & Clinical Oncology, 2010, 136(6):897-903.
[6] 嚴(yán)峻,文靜,陳海南,等.二氫青蒿素聯(lián)合替莫唑胺抑制膠質(zhì)瘤細(xì)胞增殖和誘導(dǎo)凋亡[J]. 中華實(shí)驗(yàn)外科雜志,2019,36(2):274-276.
[7] Lee D H, Hasanuzzaman M, Kwon D, et al. 10-phenyltriazoyl artemisinin is a novel p-glycoprotein inhibitor that suppresses the overexpression and function of P-glycoprotein[J]. Curr Pharm Des, 2018, 24: 5590-5597.
[8] 曹鵬,冷東瑾,李瀅,等.雙氫青蒿素抗腫瘤分子生物學(xué)機(jī)制研究進(jìn)展[J]. 浙江大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2016,45(5):501-507.
[9] 鄭鵬生,冀靜.mTOR 信號(hào)通路與腫瘤的研究進(jìn)展[J]. 西安交通大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2010,31(1):5-9.
相似文獻(xiàn)/References:
[1]李業(yè)森.68Ga標(biāo)記TMTP1探針在肝癌腫瘤模型中的microPET/CT顯像研究[J].福建醫(yī)藥雜志,2022,44(05):122.
Li Yesen.Study on microPET/CT imaging of 68GA-labeled TMTP1 probe in HCC tumor model[J].FUJIAN MEDICAL JOURNAL,2022,44(04):122.
[2]吳嘉旭,胡明超,王強(qiáng),等.NDC1基因在肝癌中的診斷及預(yù)后價(jià)值的生物信息學(xué)分析[J].福建醫(yī)藥雜志,2023,45(01):7.
WU Jiaxu,HU Mingchao,WANG Qiang,et al.Bioinformatics analysis of the diagnostic and prognostic value of NDC1 gene in liver hepatocellular carcinoma[J].FUJIAN MEDICAL JOURNAL,2023,45(04):7.